1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Tham LS, Tang CC, Choi SL, et al. Population exposure–response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. J ClinPharmacol.2014;54(10):1117-1124. http://dx.doi.org/10.1002/jcph.312
3Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-154.e9. http://dx.doi.org/10.1016/j.jaci.2012.04.024
4Wang CQF, Suárez-Fariñas M, Nograles KE, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014;134(12):2990-2993. https://doi.org/10.1038/jid.2014.268